ClinicalTrials.Veeva

Find clinical trials for Asthma in Hanyang, Seoul

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Pulmonary Eosinophilia
Allergic Rhinitis
Chronic Obstructive Pulmonary Disease
Obstructive Lung Diseases
Rhinitis
Respiration Disorders
Respiratory Tract Diseases

Asthma trials near Hanyang, Seoul, KOR:

Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma (DIRECTION)

Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Severe Uncontrolled Asthma...

Active, not recruiting
Asthma
Other: Placebo
Biological: Experimental: Tezepelumab

Phase 3

AstraZeneca
AstraZeneca

Seoul, Korea, Republic of and 70 other locations

in patients ≥ 6 to < 18 years of age with severe eosinophilic asthma, including a well-documented history of asthma exacerbations a...

Enrolling
Asthma
Drug: Benralizumab
Drug: Placebo

Phase 3

AstraZeneca
AstraZeneca

Seoul, Korea, Republic of and 80 other locations

This study will assess the efficacy and safety of dexpramipexole as an adjunctive oral therapy in participants with inadequately controlled asthma...

Enrolling
Asthma
Asthma; Eosinophilic
Drug: Placebo
Drug: Dexpramipexole Dihydrochloride

Phase 3

Areteia Therapeutics

Seoul, Korea, Republic of and 125 other locations

28-week Phase 3 Efficacy and Safety Study of Tezepelumab in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma...

Enrolling
Asthma
Other: Placebo
Biological: Tezepelumab

Phase 3

AstraZeneca
AstraZeneca

Seoul, Korea, Republic of and 121 other locations

Locations recently updated

To assess the efficacy and safety of tezepelumab in pediatric participants with severe uncontrolled asthma on medium to high-dose inhaled co...

Enrolling
Asthma
Other: Placebo
Biological: Tezepelumab

Phase 3

AstraZeneca
AstraZeneca

Seoul, Korea, Republic of and 97 other locations

This is a study of amlitelimab for the treatment of participants with moderate-to-severe asthma. The study will have a double-blind treatmen...

Enrolling
Asthma
Drug: Placebo
Drug: Amlitelimab

Phase 2

Sanofi
Sanofi

Seoul, Seoul-teukbyeolsi, Korea, Republic of and 30 other locations

trifenatate (FF/UMEC/VI) with inhaled corticosteroids/long-acting beta-2 agonists (ICS/LABA) in adult participants with uncontrolled asthma...

Not yet enrolling
Asthma
Drug: Inhaled corticosteroids/long-acting beta-2 agonists
Drug: Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate

Phase 4

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Seoul, Korea, Republic of and 67 other locations

The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function

Enrolling
Moderate to Severe Asthma
Drug: povorcitinib
Other: placebo

Phase 2

Incyte
Incyte

Seoul, Korea, Republic of and 95 other locations

and formoterol fumarate metered dose inhaler relative to budesonide metered dose inhaler in adults and adolescents with inadequately controlled asthma...

Enrolling
Asthma
Drug: BFF MDI 160/9.6 μg BID (320/19.2μg/day)
Drug: BD MDI 160 μg BID (320 μg/day)

Phase 3

AstraZeneca
AstraZeneca

Seoul, Korea, Republic of and 139 other locations

and safety of Atuliflapon administered once daily over a 12-week treatment period to adult participants with moderate to severe uncontrolled asthma...

Enrolling
Asthma
Drug: Placebo
Drug: Atuliflapon

Phase 2

AstraZeneca
AstraZeneca

Seoul, Korea, Republic of and 350 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems